Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Neuronata-R Suspended in HTS-FRS for ALS
NCT06676423Phase 1Completed
- Sponsor
- Corestemchemon
- Start
- Nov 2022
- Primary completion
- Nov 2023
- Modality
- Bone Marrow HSCs, Peripheral Blood HSCs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lenzumestrocel in amyotrophic lateral sclerosis (ALS), sponsored by Corestemchemon. Primary endpoints: Tolerability Assessment at 8 weeks and Safety Assessment at 0 days. Started Nov 2022; status: completed.
02
Drugs
lenzumestrocel
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT06676423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06676423.